• Optimi Health completed production and quality release of a batch of 5 mg naturally derived psilocybin capsules at its Princeton, B.C. cGMP facility.
• Batch allocated to a Health Canada-authorized Phase 2, multisite, open-label MDD study of up to 200 participants with a single supervised dose.
• Patient dosing expected to finish by end-2027; trial data aimed at supporting potential registration in Canada and other markets.
• Same batch also earmarked for commercial supply to Australian licensed clinics treating TRD under the TGA Authorised Prescriber Scheme.
• No percentage changes or financial results were disclosed; Optimi noted psilocybin-assisted therapy for MDD remains under investigation without Health Canada market authorization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Optimi Health Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230900PRIMZONEFULLFEED9832163) on September 23, 2026, and is solely responsible for the information contained therein.